The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1334
March 22, 2010
View Complete Issue         Table of Contents 2019 
Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation
March 22, 2010 (Issue: 1334)
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation
Article code: 1334c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.